<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tixagevimab and cilgavimab (Canada: Authorized; United States: Authorization withdrawn): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tixagevimab and cilgavimab (Canada: Authorized; United States: Authorization withdrawn): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tixagevimab and cilgavimab (Canada: Authorized; United States: Authorization withdrawn): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="134627" href="/d/html/134627.html" rel="external">see "Tixagevimab and cilgavimab (Canada: Authorized; United States: Authorization withdrawn): Drug information"</a> and <a class="drug drug_patient" data-topicid="134650" href="/d/html/134650.html" rel="external">see "Tixagevimab and cilgavimab (Canada: Authorized; United States: Authorization withdrawn): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F56959664"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Evusheld Emergency Use Authorization and Distribution Update</span>
<span class="collapsible-date">January 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">On January 26, 2023, the FDA announced that Evusheld (tixagevimab copackaged with cilgavimab) is no longer authorized in any US region due to the high frequency of circulating SARS-CoV-2 variants that are not susceptible to Evusheld. Therefore, Evusheld may not be administered for pre-exposure prophylaxis for prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency.</p>
<p style="text-indent:0em;">Further information can be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-announces-evusheld-not-currently-authorized-emergency-use-us&amp;token=TFS1yn3lT0CKRF7JmfMHHQGWyNiRr1zP%2B3t26TkeKSbMoVcc7idjvqLyIqmLQQ8Uhdlj1PRKJXiG8TGHThwt2Sg8XOInuCACRj9rkzJMTsCizE76pQi7D3skrJPmKzMGWvADjJ7UZUfa3EUqQeV5Eg%3D%3D&amp;TOPIC_ID=134628" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56455561"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Evusheld [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56774958"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Evusheld</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56430817"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F56437242"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Tixagevimab and cilgavimab have not been studied in pediatric patients; emergency use authorization from the FDA is based on likelihood of similar exposures in patients ≥12 years of age weighing ≥40 kg to those in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f025e376-5bb0-4771-af07-7550a85c2b34">COVID-19, preexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, preexposure prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Tixagevimab and cilgavimab are only for use in patients who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure, <b>and</b> either have moderate to severe immune compromise and may not mount an adequate immune response to COVID-19 vaccination, <b>or</b> who cannot be vaccinated due to a history of severe adverse reaction to COVID-19 vaccines or components. Development of SARS-CoV-2 variants with reduced susceptibility to tixagevimab and cilgavimab may increase risk of treatment failure; consider local prevalence of variants when evaluating options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>). Further information on variants may be found at: <a href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=134628" target="_blank">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents, weighing ≥40 kg: IM: Tixagevimab 300 mg and cilgavimab 300 mg, administered in 2 separate syringes consecutively, every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who initially received previously authorized dose of tixagevimab 150 mg and cilgavimab 150 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose receipt ≤3 months ago: IM: Tixagevimab 150 mg and cilgavimab 150 mg, administered in 2 separate syringes consecutively, as soon as possible. Starting 6 months after this additional dose, administer tixagevimab 300 mg and cilgavimab 300 mg, administered in 2 separate syringes consecutively, every 6 months.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose receipt &gt;3 months ago: IM: Tixagevimab 300 mg and cilgavimab 300 mg, administered in 2 separate syringes consecutively, as soon as possible; repeat every 6 months.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F56437247"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥12 years and Adolescents, weighing ≥40 kg: No dosage adjustment is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F56437248"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the fact sheet for health care providers (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F56437293"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="134627" href="/d/html/134627.html" rel="external">see "Tixagevimab and cilgavimab (Canada: Authorized; United States: Authorization withdrawn): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f025e376-5bb0-4771-af07-7550a85c2b34">COVID-19, preexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, preexposure prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients with moderate to severe immune compromise who cannot be vaccinated or may have an inadequate response to vaccination:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For patients who have received a COVID-19 vaccination, administer tixagevimab and cilgavimab ≥2 weeks after vaccination. Development of SARS-CoV-2 variants with reduced susceptibility to tixagevimab and cilgavimab may increase risk of treatment failure; consider local prevalence of variants when evaluating therapy options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>). Further information on variants may be found at: <a href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=134628" target="_blank">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Initial dosing: Tixagevimab 300 mg and cilgavimab 300 mg as a single dose (administered in 2 separate syringes consecutively). For patients who initially received tixagevimab 150 mg and cilgavimab 150 mg (previously approved dose), administer a follow-up dose of tixagevimab 150 mg and cilgavimab 150 mg (if initial dose was ≤3 months ago) or tixagevimab 300 mg and cilgavimab 300 mg (if initial dose was &gt;3 months ago) as soon as possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Repeat dosing: Tixagevimab 300 mg and cilgavimab 300 mg as a single dose (administered in 2 separate syringes consecutively) every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F56437295"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F56437296"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F56445016"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse reactions and incidences are derived from the FDA issued emergency use authorization (EUA) unless otherwise specified. Refer to EUA for information regarding reporting adverse reactions (FDA 2022). Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Nervous system: Dizziness (1%), fatigue (4%), headache (6%), insomnia (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F56430650"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity reactions, including anaphylaxis, to tixagevimab, cilgavimab, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F56437266"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: A higher rate of serious cardiovascular adverse events, including myocardial infarction and cardiac failure, was observed among recipients of tixagevimab and cilgavimab, compared to placebo. All patients who experienced cardiac events had cardiac risk factors and/or a history of cardiovascular disease, and there was no clear temporal pattern. Consider potential risk and benefit in patients with a history of cardiovascular disease and advise patients to seek immediate medical attention if they experience signs/symptoms of a cardiovascular event (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of human IgG<sub>1</sub> monoclonal antibodies like tixagevimab and cilgavimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care. Monitor patients after administration for ≥1 hour. Additionally, tixagevimab and cilgavimab contain polysorbate 80, an ingredient in some COVID-19 vaccines; polysorbate 80 is also structurally similar to polyethylene glycol, an ingredient in some other COVID-19 vaccines. Consider consultation with an allergist/immunologist prior to administering tixagevimab and cilgavimab to individuals who have experienced a severe hypersensitivity reaction (eg, anaphylaxis) to a COVID-19 vaccine (FDA 2022). See also “Polysorbate 80” warning below.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>• Bleeding disorders: Administer with caution to individuals with thrombocytopenia or any coagulation disorder (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> • </b>Polysorbate 80: Tixagevimab and cilgavimab contains polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• SARS-CoV-2 viral variants: Certain SARS-CoV-2 viral variants may not be neutralized by monoclonal antibodies such as tixagevimab and cilgavimab. Tixagevimab and cilgavimab may not be effective at preventing COVID-19 caused by these variants. If signs or symptoms of COVID-19 occur, advise patients to test for COVID-19 and seek medical attention, including treatment, as necessary.</p></div>
<div class="block prod-avail drugH1Div" id="F56430656"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Investigational agent; approved for emergency use authorization by the FDA December 2021.</p></div>
<div class="block foc drugH1Div" id="F56455562"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evusheld: Tixagevimab 150 mg and cilgavimab 150 mg per 1.5 mL (3 mL [DSC]) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F56455560"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56552453"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Evusheld Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 &amp; 150 mg/1.5 mL (per mL): $0.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56774959"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evusheld: Tixagevimab 150 mg and cilgavimab 150 mg per 1.5 mL (3 mL) [contains polysorbate 80]</p></div>
<div class="block accres drugH1Div" id="F56437262"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:-2em;margin-left:2em;">Tixagevimab and cilgavimab are not commercially available; they are available under an emergency use authorization (EUA) from the FDA. The US Department of Health and Human Services will determine distribution amounts for each state/territory based on total adult population within the jurisdiction. State and territorial health departments will identify which sites in their respective jurisdictions receive product.</p>
<p style="text-indent:-2em;margin-left:2em;">As part of the EUA, information consistent with fact sheets pertaining to emergency use of tixagevimab and cilgavimab are required to be available for health care providers and patients/caregivers, and certain mandatory requirements for the combination's administration under the EUA must be met as outlined in the FDA EUA letter; the fact sheets and EUA letter may be accessed at https://www.evusheld.com/. Additionally, health care providers must track and report all medication errors and serious adverse events potentially associated with tixagevimab and cilgavimab use by either submitting a MedWatch form (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch%2Freport.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPNcm5lNJ%2BSfidIV4m5OTN5Ih2EApxCjHbBkH0Y1jxFob&amp;TOPIC_ID=134628" target="_blank">https://www.fda.gov/medwatch/report.htm</a>) or an FDA Form 3500 (health professional) by mail or fax (1-800-FDA-0178); a copy of all MedWatch forms should also be provided to AstraZeneca (fax 1-866-742-7984).</p></div>
<div class="block admp drugH1Div" id="F56437252"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM: Administer tixagevimab and cilgavimab as 2 separate IM injections; administer consecutively. Administer each injection at a different site, preferably 1 in each gluteal muscle; ensure that administration sites are appropriate for dose volume (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F56437297"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IM:</b> Administer tixagevimab and cilgavimab as 2 separate consecutive IM injections. Administer at different injection sites, preferably 1 in each of the gluteal muscles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USFDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USFDA.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F56437282"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.</p>
<p style="text-indent:-2em;margin-left:2em;">Prepared syringes should be administered as soon as possible. If immediate administration is not possible, store syringes for up to 4 hours refrigerated at 2°C to 8°C (36°F to 46°F) or at room temperature (up to 25°C [77°F]) (FDA 2022).</p></div>
<div class="block usep drugH1Div" id="F56430815"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Investigational agent for preexposure prophylaxis of COVID-19 in patients who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure <b>and </b>either have moderate to severe immune compromise and may not mount an adequate immune response to COVID-19 vaccination, <b>or</b> who cannot be vaccinated due to a history of severe adverse reaction to COVID-19 vaccines or components (FDA issued emergency use authorization [EUA] in ages ≥12 years weighing ≥40 kg and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Under the EUA, medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include, but are not limited to:</p>
<p style="text-indent:-2em;margin-left:4em;">• Active treatment for solid tumor and hematologic malignancies</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic malignancies associated with poor responses to COVID-19 vaccines (eg, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) regardless of current treatment status</p>
<p style="text-indent:-2em;margin-left:4em;">• Receipt of solid-organ or islet transplant and taking immunosuppressive therapy</p>
<p style="text-indent:-2em;margin-left:4em;">• Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">• Moderate or severe primary immunodeficiency (eg, common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV infection (advanced or untreated)</p>
<p style="text-indent:-2em;margin-left:4em;">• Active treatment with any of the following: High-dose corticosteroids (ie, ≥20 mg/day prednisone or equivalent for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (eg, B-cell depleting agents).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: In the US, tixagevimab and cilgavimab are NOT authorized for treatment or postexposure prophylaxis of COVID-19. Use of tixagevimab and cilgavimab as preexposure prophylaxis is NOT a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended (FDA 2022).</p></div>
<div class="block cyt drugH1Div" id="F56459856"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56459853"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Tixagevimab and Cilgavimab may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Wait at least 2 weeks after receipt of a COVID-19 vaccine before administering tixagevimab and cilgavimab for pre-exposure prophylaxis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F56437264"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nonclinical reproductive toxicity studies have not been conducted (FDA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Tixagevimab and cilgavimab are both humanized monoclonal antibodies (IgG<sub>1</sub>). Human IgG crosses the placenta. Exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of severe morbidity and mortality from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID-19. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO). Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2022).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the therapeutic management of COVID-19 infection during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process (NIH 2022). Dose adjustments are not recommended for patients who are pregnant (FDA 2022). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor maternal and infant outcomes following exposure to COVID-19 during pregnancy is ongoing. Health care providers are encouraged to enroll patients exposed to COVID-19 during pregnancy in the Organization of Teratology Information Specialists pregnancy registry (1-877-311-8972; https://mothertobaby.org/join-study/).</p></div>
<div class="block mopp drugH1Div" id="F56437253"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity reactions (including anaphylaxis) for ≥1 hour following injections.</p></div>
<div class="block pha drugH1Div" id="F56437284"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tixagevimab and cilgavimab are recombinant human IgG1κ monoclonal antibodies that bind to nonoverlapping epitopes of the spike protein receptor–binding domain of SARS-CoV-2, blocking attachment to the human ACE2 receptor. Tixagevimab and cilgavimab have amino acid substitutions to extend half-life, reduce antibody effector function, and minimize the potential risk of antibody-dependent disease enhancement (FDA 2022).</p></div>
<div class="block phk drugH1Div" id="F56437285"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Tixagevimab: 7.7 ± 1.97 L; Cilgavimab: 8.7 ± 2.73 L (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tixagevimab: 68.5%; Cilgavimab: 65.8% (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Tixagevimab: 87.9 ± 13.9 days; Cilgavimab: 82.9 ± 12.3 days (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Tixagevimab: 14.9 days (range: 1.1 to 86 days); Cilgavimab: 15 days (range: 1.1 to 85 days) (FDA 2022).</p></div>
<div class="block phksp drugH1Div" id="F56437232"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clinical trials have not been performed; serum exposures in patients ≥12 years of age and weighing ≥40 kg are expected to be similar to those observed in adults (FDA 2022).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol.</i> 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Evusheld (tixagevimab and cilgavimab) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated January 5, 2022. Accessed January 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tixagevimab-and-cilgavimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USFDA.1">
<a name="USFDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab and cilgavimab). https://www.evusheld.com/. Published January 2023. Accessed January 1, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 134628 Version 51.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
